Wedbush's Dan Ives sees 60% near-term upside for Tesla shares. Elon Musk may have new responsibilities with the U.S. government, but he's proven he can balance a massive workload. If Tesla ...

Wedbush analyst R. Anderson now forecasts that the real estate investment trust will post earnings per share of $1.46 for the year, down from their previous forecast of $1.55.

The primary spending impact will be in the Banking, Financial Services and Insurance (BFSI) and High-Tech verticals, according to the note. According to Katri, there are no signs of a slowdown in ...

Wedbush analyst David Nierengarten maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $18. ...

Dan Ives, Global Head of Technology Research at Wedbush Securities, talks about how Deepseek has transformed China's role in the global AI revolution, where Alibaba fits into it, and the new 'arms ...

Coronation Street star Geoffrey Hinsliff left over £330,000 in his will - mostly to his wife. The Leeds-born actor played cabbie Don Brennan in the ITV soap for 10 years from 1987. Audiences were ...

The duo clash in a deadly conflict as retirement home residents in the psychological thriller, which is set to hit theaters March 7 before streaming on Shudder. By Etan Vlessing Canada Bureau ...

Police are asking for the public's help in the search for missing Hikumutu man Geoffrey Kelly. Police said Kelly was last seen on Thursday night, wearing grey knee-length shorts, jandals, a tan ...

Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share.

Investing.com -- Procter & Gamble (NYSE:PG)'s (P&G) shares initially dipped 2.5% before erasing losses to trade in the green after the company's Chief Financial Officer, Andre Schulten, commented ...